Mary Ann Liebert, Inc., in partnership with the Rosalind Franklin Society has launched a prestigious annual award to recognize outstanding published peer-reviewed research by women and underrepresented minorities in science in each of the publisher’s peer-reviewed journals. The RFS / MAL Award in Science for Human Gene Therapy has selected Hildegard Büning, PhD who co-authored Capsid-Engineering for Central Nervous System-Directed Gene Therapy with Adeno-Associated Virus Vectors.
Follow us on Twitter! @HGTJournal
Scientific Abstracts from ESGCT 29th Annual Congress in Collaboration With BSGCT
Human Gene Therapy is pleased to provide complimentary access to the scientific abstracts from the ESGCT 29th Annual Congress in Collaboration With BSGCT. The annual meeting took place on October 11-14, 2022 in Edinburgh, UK.
Resources for the Human Gene Therapy Community:
- On Demand Webinar on Advanced Cell and Gene Therapies Using a Closed System...Watch Now
- On Demand Webinar on Home-Cage Monitoring 24/7: Improving Research Reproducibility and Outcomes...Watch Now
- eBook: Tools for Analytical Characterization of Adeno-Associated Viruses
- eBook: “All in One” 24/7 home cage monitoring: Improving model translation, animal welfare and data reproducibility
- Expert Roundtable: Roundtable Discussion on Leaps in Innovation in Cancer Immunology
- Expert Roundtable: Home-Cage Monitoring and its Effects on Research Capability and Outcomes
- Gene and Cell Therapy Connect — a free, comprehensive news source delivered bimonthly to readers. Sign up or View the archive
Aims & Scope
Human Gene Therapy (HGT) is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes important advances in DNA, RNA, cell and immune therapies, validating the latest advances in research and new technologies.
Established in 1990, HGT provides a prestigious forum for publishing scientific and clinical research, including ethical, legal, regulatory, social, and commercial issues, which enables the advancement and progress of therapeutic procedures leading to improved patient outcomes, and ultimately, to curing diseases.
HGT is published 12 times per year, including sections on Methods (product testing and development) and Clinical Development (regulatory review, toxicology and commercial development). The journal also publishes a wide range of reviews, commentaries and editorials.
- Basic and clinical advances in gene therapy
- Delivery systems
- Cell therapy
- Clinical genome editing
- Small nucleic acid therapeutics, including RNAi
- Clinical trials (including confirmatory or negative results)
- Improvements in vector developments
- Animal models
- Pre-clinical animal/in vitro studies to assess safety of gene and cell therapy products
- Clinical protocols
- Commercial development of gene and cell therapy products
Human Gene Therapy was the first journal devoted to cover the field of gene therapy. It has been voted one of the most influential journals in Biology and Medicine by the Biomedical & Life Sciences Division of the Special Libraries Association.
Human Gene Therapy is under the editorial leadership of Editor-in-Chief Terence R. Flotte, MD, University of Massachusetts Medical School and other leading investigators. View the entire editorial board.
Audience: Geneticists, medical geneticists, molecular biologists, virologists, experimental researchers, and experimental medicine specialists, among others.
Human Gene Therapy and HGT Methods provide “Instant Online” publication 72 hours after acceptance
- PubMed Central
- Web of Science: Science Citation Index Expanded™ (SCIE)
- Web of Science: Science Citation Index® (SCI)
- Current Contents®/Life Sciences
- Biotechnology Citation Index®
- Biological Abstracts
- BIOSIS Previews
- Journal Citation Reports/Science Edition
- EMBASE/Excerpta Medica
- Chemical Abstracts
- ProQuest databases